Antibody Drug Conjugates and Bioconjugation

As pioneers in the highly potent landscape for over 14 years, CARBOGEN AMCIS has successfully delivered a significant number of drug-linker projects. Our first Antibody Drug Conjugates (ADC) project was delivered in 2005. Since then, our customers, ranging from small biotech to large pharmaceutical companies, have taken full advantage of our ADC and bioconjugation capabilities.

Our state-of-the-art bioconjugation facility, staffed with a dedicated team of experts, has been in operation for several years and can support you in conceptualizing and delivering the best linker and conjugation strategy.

Our ADC suite is directly supported by both our small molecule development capabilities and our formulation expertise that provide an end-to-end solution, in order to rapidly progress your New Chemical Entities (NCE) in support of your goals.